ImmunityBio (IBRX) Financial Analysis & Valuation | Quarter Chart

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells... more
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat ... more

Company facts

Reported company information and share structure.

Company Share structure
Market Cap$8.28BExchangeNASDAQ
SectorHealthcareIndustryBiotechnology
CountryUSCEORichard Gerald Adcock
IPO Date2015-07-28CAGR54.76%
Employees688Websiteimmunitybio.com
Div. YieldPayout Ratio
Buy Back Yield0.04%Total Yield0.04%
IBRX chart loading...

Key metrics

Reported fundamentals and market-derived technical indicators.

Fundamentals Technicals
EV$9.78BP/E-8.15Forward P/E-62.45PEG
P/S327.65P/B-51.96P/CF-390.96P/FCF-384.26
Sales$165.79MSales 1Y192.92%Sales 3Y27905.41%Sales 5Y25406.46%
EPS$-0.97EPS 1Y110.14%EPS 3Y-20.2%EPS 5Y23.24%
Sales QoQ15.91%EPS QoQ-64.52%Sales QoQ Avg18.03%EPS QoQ Avg196.27%
Gross Margin94.63%Operating Margin-151.88%Profit Margin-598.56%ROCE-45.63%
ROA-158%ROE135%Altman Z Score-0.3Piotroski Score4
Current Ratio4.66Quick Ratio4.66Cash Ratio0.99Op. CF Ratio-0.87
Debt/Equity-0.04Debt/Assets0.06Lt Debt/Equity-0.03Lt Debt/Cap.-0.03
Intrst Cov.-3.64Inventory TurnoverAsset Turnover0.26Receivables Turnover
Enterprise Value$9.78BP/E Ratio-8.15
Forward P/E-62.45PEG Ratio
P/S Ratio327.65P/B Ratio-51.96
P/CF Ratio-390.96P/FCF Ratio-384.26
EPS$-0.97EPS Growth 1Y110.14%
EPS Growth 3Y-20.2%EPS Growth 5Y23.24%
Revenue Growth 1Y192.92%Gross Margin0.95%
Operating Margin-1.52%Profit Margin-5.99%
ROE1.35%ROA-1.58%
ROCE-0.46%Current Ratio4.66
Quick Ratio4.66Cash Ratio0.99
Debt/Equity-0.04Interest Coverage-3.64
Altman Z Score-0.3Piotroski Score4

ImmunityBio (IBRX) valuation & financials

ImmunityBio (IBRX) has a market capitalization of $8.28B and trades at a price-to-earnings ratio of -8.2. It operates in the Healthcare sector (Biotechnology).

ImmunityBio's revenue grew +192.9% over the last year.

ImmunityBio's next earnings report is scheduled for November 3, 2026 before market open; analysts estimate EPS of $-0.08. Check the earnings calendar to see all companies reporting this week.

📈 Analysts estimate IBRX EPS of $-0.08 for the upcoming quarter. See ImmunityBio revenue & EPS analyst forecasts for the next four quarters with Quarter Chart Premium.

ImmunityBio (IBRX) — frequently asked questions

When does ImmunityBio (IBRX) report earnings next?

ImmunityBio is expected to report earnings on November 3, 2026 before market open. Analysts estimate EPS of $-0.08.

What is ImmunityBio's market cap?

ImmunityBio (IBRX) has a market capitalization of $8.28B.

What is IBRX's P/E ratio?

ImmunityBio trades at a price-to-earnings ratio of -8.2, with trailing twelve-month EPS of $-0.97.

How fast is ImmunityBio growing?

ImmunityBio's revenue grew +192.9% over the last year.

Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)